Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - An injection of expediency?

Clinical Endocrinology

Volumn 54, Issue 1, 2001, Pages 11-13

  James, R A ^a   Gilroy, J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ACROMEGALY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; GROWTH INHIBITION; HEADACHE; HORMONE INHIBITION; HUMAN; LETHARGY; NOTE; PARESTHESIA; PRIORITY JOURNAL; SNORING; SWEATING;

ACROMEGALY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; PEPTIDES, CYCLIC; RANDOMIZED CONTROLLED TRIALS; SOMATOSTATIN;

EID: 0035135360     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01202.x     Document Type: Note

References (14)

1. SMS 201-995: A very potent and selective analog of somatostatin with prolonged action
2. In vitro and in vivo evaluation of a somatostatin analogue released form PLGA microspheres
3. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
4. Lanreotide 60 mg in well-controlled acromegalic patients
5. Outcome of 23 patients with acromegaly treated with lanreotide autogel - A new long-acting somatostatin analogue for subcutaneous injection
6. Actions of growth hormone release inhibitory hormone in healthy men and in acromegaly
7. A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly
8. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration
9. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly
10. Octreotide as primary therapy for acromegaly
11. Ballière-Tindall's Best Practice & Research
12. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
13. Premieres observations sur le mode d'action de la somatostatine, un facteur hypothalamique qui inhibe la secretion de l'hormone de croissance
14. Tachyphylaxis to octreotide in a patient with acromegaly